203例使用奈玛特韦/利托那韦患者的联合用药情况分析  

Analysis of the Combination in 203 Patients Treated with Nematavir/Ritonavir

作　　者：蔡泓敏[1] 朱红 陆红柳[1] 张楠[1] 闫阔 杨啸白[1] 李桃园[1] CAI Hongmin;ZHU Hong;LU Hongliu;ZHANG Nan;YAN Kuo;YANG Xiaobai;LI Taoyuan(Dept.of Pharmacy,Beijing Chuiyangliu Hospital,Beijing 100022,China)

机构地区：[1]北京市垂杨柳医院药剂科,北京100022

出　　处：《中国医院用药评价与分析》2023年第12期1508-1511,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：首都临床特色应用研究项目(No.Z181100001718125)。

摘　　要：目的:通过对使用新型抗病毒药奈玛特韦/利托那韦患者的联合用药情况进行分析,探讨奈玛特韦/利托那韦临床药学监护要点。方法:统计2022年12月至2023年2月该院203例使用奈玛特韦/利托那韦患者的基本情况、用药情况等,从药品不良反应、药物相互作用及中西药联合应用等方面探讨药学监护要点。结果:203例使用奈玛特韦/利托那韦的患者中,有110例联合应用与其有相互作用的西药,129例联合应用中成药,64例同时联合应用西药和中成药。联合用药的患者中,18例发生药品不良反应,包括奈玛特韦/利托那韦与阿托伐他汀联合应用9例,表现为肝酶异常,其中6例同时联合应用中成药;奈玛特韦/利托那韦与托伐普坦联合应用4例,表现为血钾水平异常,其中2例联合应用中成药。结论:奈玛特韦/利托那韦与多种药物存在相互作用,联合应用时可能会增加药品不良反应风险,中西药联合治疗需整体评估药物相互作用,个体化调整治疗方案,并加强药学监护。OBJECTIVE:To analyze the combination in patients treated with the novel antiviral drug nirmatrelvir/ritonavir,and to explore the key points of clinical pharmaceutical care of nirmatrelvir/ritonavir.METHODS:General information and drug use of 203 patients with nirmatrelvir/ritonavir in the hospital from Dec.2022 to Feb.2023 were analyzed,and the key points of pharmaceutical care were discussed from the aspects of adverse drug reactions,drug interactions and the combined application of Chinese and Western medicines.RESULTS:Among the 203 patients treated with nirmatrelvir/ritonavir,110 patients were treated with Western medicines interacting with nirmatrelvir/ritonavie,129 patients additionally received Chinese patent medicines,and 64 patients received combination therapy of Western and Chinese patent medicines.Among the patients with drug combination,18 cases had adverse drug reactions,including 9 cases of nirmatrelvir/ritonavir combined with atorvastatin,showing abnormal liver enzymes,6 cases of which were combined with Chinese patent medicines.Abnormal blood potassium levels were observed in 4 cases of nirmatrelvir/ritonavir combined with tolvaptan,2 of which were combined with Chinese patent medicines.CONCLUSIONS:Nirmatrelvir/ritonavir interacts with a variety of drugs and may increase the risk of adverse drug reactions when applied in combination.Combination therapy with Chinese and Western medicines requires an overall assessment of drug interactions,individualized adjustment of treatment regimens,and enhanced pharmacological monitoring.

关 键 词：奈玛特韦/利托那韦 药物相互作用 药学监护 不良反应 

分 类 号：R978.7[医药卫生—药品]